Gene Therapies for Rare and Genetic Diseases, 2018 Report - Recent Advances & Clinical Trials - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 14, 2018--The “Gene Therapies for Rare and Genetic Diseases” report has been added to ResearchAndMarkets.com’s offering.
This edition of the Genetic Technology TOE provides insights across recent developments in gene therapies for rare and genetic disorders. The TOE also provides a clinical trial analysis for ex vivo gene therapy.
The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions.
The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.
Key Topics Covered:
Recent Advances in Gene Therapies that Address Rare and Genetic DiseasesGene Therapy for Rare Neurological Genetic Diseases Autologous Ex Vivo Gene Therapy for Neurodegenerative Disorders Orphan Drug Accelerators to Improve Rare Diseases Business Model Lentiviral Gene Therapy Solutions for Rare and Genetic Diseases
Clinical Trial Analysis and Key ContactsClinical Trial Analysis for Ex Vivo Gene Therapy Key Contacts
For more information about this report visit https://www.researchandmarkets.com/research/r2ljqx/gene_therapies?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181214005523/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH GENETICS
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 12/14/2018 03:31 PM/DISC: 12/14/2018 03:31 PM